Former President and Chief Operating Officer · Keros Therapeutics, Inc. (KROS)

Christopher Rovaldi

FY2025 is the first fiscal year CompBrief holds for Christopher Rovaldi as a named executive officer of Keros Therapeutics; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2025

$1,476,114

Compensation figures as of the proxy filed April 22, 2026 (DEF 14A).

Christopher Rovaldi compensation by year

Keros Therapeutics Summary Compensation Table · the one fiscal year held
In US dollars, as Keros Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2025
Salary$578,923
Bonus$0
Stock awards$871,200
Option awards$0
Non-equity incentive$0
Pension and deferred compensation$0
All other$25,990
Total$1,476,114

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Keros Therapeutics, Inc. DEF 14A filed April 22, 2026, accession 0001104659-26-046791, and prior-year filings. Open the filing on EDGAR.

Keros Therapeutics’s named executive officers, FY2025

as the company reported each
Named executive officerRoleFY2025 total
Jasbir SeehraPresident and Chief Executive Officer$2,540,204
Christopher Rovaldi · this pageFormer President and Chief Operating Officer$1,476,114
Keith RegnanteChief Financial Officer$1,113,872
Esther ChoChief Legal Officer and Secretary$1,098,832

The full Keros Therapeutics compensation record

free company brief

This page is one person within Keros Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Keros Therapeutics's full Executive Compensation Report with peer benchmarking.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Keros Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Velarion Pro: every company page, peer tools and exports, one seat

One email to you when Pro opens, and nothing else. Privacy